Beximco Pharmaceuticals (DHA:BXPHARMA) Other Current Payables: BDT138 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:BXPHARMA Beximco Pharmaceuticals PLC DHA:BXPHARMA
94 GF Score
Price BDT147.80
GF Value BDT128.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Other Current Payables?

Beximco Pharmaceuticals DHA:BXPHARMA +1.86% 94 Other Current Payables is BDT138 Mil as of Mar. 2026. GuruFocus rates DHA:BXPHARMA with a GF Score™ of 94/100 and a GF Value™ of BDT128.73 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Beximco Pharmaceuticals's Other Current Payables for the quarter that ended in Mar. 2026 was BDT138 Mil.

Beximco Pharmaceuticals's quarterly Other Current Payables increased from Sep. 2025 (BDT138 Mil) to Dec. 2025 (BDT159 Mil) but then declined from Dec. 2025 (BDT159 Mil) to Mar. 2026 (BDT138 Mil).

Beximco Pharmaceuticals's annual Other Current Payables increased from Jun. 2023 (BDT402 Mil) to Jun. 2024 (BDT551 Mil) and increased from Jun. 2024 (BDT551 Mil) to Jun. 2025 (BDT649 Mil).

Beximco Pharmaceuticals Other Current Payables Related Terms

Beximco Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Other Current Payables Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 214.81 193.85 401.51 551.38 648.55

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 648.55 138.41 158.64 137.93
DHA:BXPHARMA
94GF Score
Beximco Pharmaceuticals PLC DHA:BXPHARMA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of BDT138 Mil mean?
Beximco Pharmaceuticals (DHA:BXPHARMA) has a Other Current Payables of BDT138 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Other Current Payables too high?
Beximco Pharmaceuticals' current Other Current Payables is BDT138 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Other Current Payables compare to ZTS and UTHR?
Beximco Pharmaceuticals' Other Current Payables of BDT138 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Other Current Payables is BDT138 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (DHA:BXPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT128.73, compared to a current price of BDT147.80 — trading 14.8% above its estimated fair value. The current Other Current Payables is BDT138 Mil. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Beximco Pharmaceuticals (DHA:BXPHARMA), the current Other Current Payables is BDT138 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (DHA:BXPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of BDT147.80 is trading 14.8% above its estimated GF Value™ of BDT128.73. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for DHA:BXPHARMA:

  • Other Current Payables: BDT138 Mil
  • GF Value™: BDT128.73 vs. price of BDT147.80 (14.8% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the DHA:BXPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Other Exchanges BXP:UKR2WA:Germany
Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
94GF Score

Get the complete analysis for DHA:BXPHARMA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT147.80
Price
BDT128.73
GF Value